What pharmacologic consideration is critical for a patient on sedatives during air transport?

• A. Sedatives have no impact on respiration and require no monitoring.
• B. Potential respiratory depression, altered pharmacokinetics in flight, and need for continuous monitoring.
• C. Pharmacokinetics are unchanged in flight.
• D. Only consider sedation if the patient is stable.

Answer: (B)

Sedatives during air transport require attention to two realities: they can depress respiration, and the flight environment can alter how the drug behaves in the body. Sedatives blunt the respiratory drive, which becomes riskier in the cabin where oxygen is reduced and hypoventilation can more quickly lead to hypoxemia or hypercapnia. At the same time, flight physiology—changes in cardiac output, volume status, temperature, and stress—can shift pharmacokinetics, altering absorption, distribution, metabolism, and elimination. Because of this combination, continuous monitoring is required to detect ventilation changes, ensure adequate oxygenation, and allow timely intervention or dose adjustments. The other notions ignore the respiratory risk, claim pharmacokinetics stay the same in flight, or suggest waiting until stability—none align with the need for vigilance and preparedness in aeromedical transport.